β-elemene inhibits non-small cell lung cancer cell migration and invasion by inactivating the FAK-Src pathway

Hongbo Zhang1, Shaobing Li2, Jun Bao3

  • 1Department of Radiology, The First Affiliated Hospital of USTC, Division of Life and Medicine, University of Science and Technology of China, Hefei, Anhui 230031, P.R. China.

Insights

Beta-elemene effectively inhibits non-small cell lung cancer (NSCLC) cell migration and invasion. This compound targets focal adhesion kinase (FAK)-Src signaling pathways, offering a potential new therapeutic strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Lung cancer prognosis remains poor with limited therapeutic options.
  • Cell migration and invasion are critical for lung cancer metastasis.
  • Focal adhesion kinase (FAK)-Src signaling is implicated in cancer cell motility.

Purpose of the Study:

  • To investigate the role of beta-elemene in non-small cell lung cancer (NSCLC) cell motility.
  • To elucidate the underlying mechanism of beta-elemene's anti-cancer effects, specifically its impact on FAK-Src signaling.

Main Methods:

  • Wound-healing and Transwell assays were used to assess cell migration and invasion.
  • Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analyzed motility-associated gene expression.
  • Western blotting detected phosphorylated focal adhesion kinase (FAK) and Src levels.

Main Results:

  • Beta-elemene significantly inhibited the migration and invasion of A549 and NCI-H1299 (H1299) NSCLC cell lines.
  • Exposure to beta-elemene altered the expression of motility-related genes, including RhoA, Rac1, Cac42, MMP2, and MMP9.
  • Beta-elemene treatment reduced the activity of FAK and Src signaling pathways.

Conclusions:

  • Beta-elemene demonstrates potent anti-motility effects in NSCLC cells.
  • The mechanism involves the inhibition of FAK-Src signaling.
  • Beta-elemene represents a promising therapeutic agent for NSCLC treatment.